The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Clinical trail of palonosetron hydrochloride on preventing chemotherapy-induced vomiting for advanced gastric cancer
Author(s): 
Pages: 391-392
Year: Issue:  5
Journal: Chinese Journal of Clinical Oncology and Rehabilitation

Keyword:  盐酸帕洛诺司琼 晚期胃癌 化疗 呕吐;
Abstract: 目的探讨盐酸帕洛诺司琼和盐酸托烷司琼预防晚期胃癌因全身化疗引起呕吐的疗效和安全性。方法采用随机对照双盲设计方法,选择60例含铂类和(或)5-Fu方案全身化疗的晚期胃癌患者,分别采用盐酸帕洛诺司琼和盐酸托烷司琼止吐,化疗后5d内观察患者呕吐状况及不良反应。结果化疗后24h内,盐酸帕洛诺司琼组0度呕吐为21例,盐酸托烷司琼组0度呕吐为13例。24~120h内,盐酸帕洛诺司琼组0度呕吐为18例,盐酸托烷司琼组0度呕吐为10例。使用盐酸帕洛诺司琼与盐酸托烷司琼后预防急性及延迟性呕吐的疗效比较差异均有统计学意义(P<0.05),而其不良反应比较差异无统计学意义。结论盐酸帕洛诺司琼预防晚期胃癌化疗所致呕吐的疗效优于盐酸托烷司琼,其不良反应发生率低,安全性好。
Related Articles
loading...